Navigation Links
Planning for bacteria in cancer patients may help hospitals fight infections
Date:1/23/2013

What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study published in this month's issue of the International Journal of Infectious Diseases shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.

"These are really dangerous infections. You think about Klebsiella it can develop resistance really quickly. And these patients have generally been in and out of hospitals. If you can't treat the infection early, it can quickly become a serious and life threatening condition," says Andrs Felipe Henao-Martnez, MD, clinical fellow in infectious diseases at the CU Cancer Center and University of Colorado Hospital.

His study looked at 462 patients with bacterial blood stream infections who were admitted to hospitals for treatment. Of these patients, 203 had cancer and 259 did not, allowing Henao-Martnez and colleagues to explore the clinical and microbiological differences between these populations. Interestingly, Henao-Martnez could show that most infections existing in cancer patients were acquired in hospital settings and not in the community, while non-cancer patients typically had community-acquired infections.

"Normally every hospital has a spreadsheet, an antibiogram, listing the bacteria and their rate of antibiotic resistance they've found in their patient population. But if you can predict ahead of time what bacteria you're likely to encounter, you can prescribe more targeted antibiotic therapy before infections create complications," Henao-Martnez says.

For example, previous treatment with aminopenicillins, like amoxicillin, and the presence of cancer seemed to significantly increase the likelihood of Klebsiella infection .

"Klebsiella pneumoniae is largely resistant to amoxicillin with the immune system compromised by the cancer and by chemotherapy, and with other bacteria largely wiped away by the amoxicillin class of antibiotics it appears that Klebsiella is left to flourish with little competition in patients with cancer" Henao-Martnez says.

The group recently submitted a paper detailing genetic differences in outcomes in this population of bacterially infected patients admitted for treatment.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Bloomberg School receives $28 million for family planning advocacy
2. Career Planning for Research Bioscientists
3. Virtual plant planning, retrofitting and maintenance
4. SeaSketch, the next generation of UCSBs MarineMap program, will aid marine spatial planning
5. NOAA science supports New Yorks offshore energy planning
6. Study: Odd biochemistry yields lethal bacterial protein
7. Antibacterial agent used in common soaps found in increasing amounts in freshwater lakes
8. Stopping smoking reduces risk of bacterial pneumonia in people with HIV
9. Designer bacteria may lead to better vaccines
10. MBL scientists find bipolar marine bacteria, refuting everything is everywhere idea
11. The saline hiding places for bacteria in Río Tinto could be like those on Mars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology: